The Lonza Board of Directors announced the nomination of Stephen Fry as an Independent Member of the Board, with his election to be decided at the Lonza Group Annual General Meeting in May 2026. If elected, Fry will also join the People and Governance Committee and the Audit and Compliance Committee, bringing pharmaceutical industry experience and organizational transformation expertise to the Swiss contract development and manufacturing organization. Fry's nomination represents Lonza's strategic emphasis on governance and performance culture as the company navigates the evolving healthcare landscape.
With more than three decades at Eli Lilly and Company, where he ultimately served as Executive Vice President and Chief Human Resources Officer for twelve years, Fry developed expertise in large-scale organizational change, high-performance culture development, and executive leadership during periods of significant industry transformation. His background complements Lonza's existing board capabilities as the company works to attract and retain world-leading talent. Jean-Marc Huet, Chairman of the Lonza Board, stated that Fry brings extensive international experience, combined with a strong track record in organizational governance, succession planning and people strategy development, and will play an important role in helping develop and embed Lonza's performance culture.
The nomination comes as Lonza continues to expand its global operations across five continents, with approximately 20,000 employees working alongside pharmaceutical and biotech companies to develop viable therapies. As the world's largest contract development and manufacturing organization dedicated to healthcare, Lonza generated sales of CHF 6.5 billion with a CORE EBITDA of CHF 2.1 billion in Full-Year 2025. Additional information about the company's operations and financial performance is available at https://www.lonza.com.
Beyond his pharmaceutical industry experience, Fry serves as a Member of the Board of Trustees at the University of Indianapolis, adding educational governance experience to his qualifications. His appointment to Lonza's board committees would place him in oversight roles for both human capital strategy and financial compliance, reflecting the comprehensive nature of his expected contributions. The nomination underscores Lonza's commitment to strengthening governance structures as the company supports customers in bringing life-saving and life-enhancing treatments to patients worldwide through cutting-edge science and manufacturing capabilities. This move signals Lonza's recognition that effective governance and talent management are critical components for sustained growth in the competitive pharmaceutical development and manufacturing sector.
